Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Editas Medicine Inc

EDIT
Current price
1.54 USD -0.07 USD (-4.35%)
Last closed 1.56 USD
ISIN US28106W1036
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 134 772 304 USD
Yield for 12 month -71.32 %
1Y
3Y
5Y
10Y
15Y
EDIT
21.11.2021 - 28.11.2021

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Address: 11 Hurley Street, Cambridge, MA, United States, 02141

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.75 USD

P/E ratio

Dividend Yield

Current Year

+32 314 000 USD

Last Year

+78 123 000 USD

Current Quarter

+30 604 000 USD

Last Quarter

+61 000 USD

Current Year

+32 314 000 USD

Last Year

-99 528 000 USD

Current Quarter

+30 604 000 USD

Last Quarter

-1 538 000 USD

Key Figures EDIT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -233 111 008 USD
Operating Margin TTM -112.28 %
Price to Earnings
Return On Assets TTM -35.52 %
PEG Ratio
Return On Equity TTM -98.10 %
Wall Street Target Price 3.75 USD
Revenue TTM 32 314 000 USD
Book Value 1.62 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -49.00 %
Dividend Yield
Gross Profit TTM -166 932 992 USD
Earnings per share -2.88 USD
Diluted Eps TTM -2.88 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics EDIT

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History EDIT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio TTM
Last Split Date

Stock Valuation EDIT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.25
Price Sales TTM 4.17
Enterprise Value EBITDA -1.36
Price Book MRQ 1.00

Financials EDIT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators EDIT

For 52 weeks

0.91 USD 6.69 USD
50 Day MA 1.49 USD
Shares Short Prior Month 13 149 670
200 Day MA 2.64 USD
Short Ratio 5.06
Shares Short 12 684 584
Short Percent 19.34 %